Share on

Global Psoriasis Drugs Market Size, Share, Trends, COVID-19 Impact & Growth Analysis Report – Segmented By Drug Type, Route of Administration, Target & Region – Industry Forecast (2022 to 2027)

Published: January, 2022
ID: 1635
Pages: 182
Formats: report pdf report excel report power bi report ppt

Global Psoriasis Drugs Market Size (2022 to 2027)

The size of the global psoriasis drugs market is expected to be worth USD 13.35 billion by 2027 from USD 9.39 billion in 2022, growing at a CAGR of 7.30% from 2022 to 2027.

Global Psoriasis Drugs Market Share Insights:

  • Based on drug type, the pharmaceuticals segment had the leading share of the global psoriasis drugs market in 2021.
  • Based on route of administration, the topical segment accounted for the major share of the market in 2021.
  • Based on target, the TNF segment led the psoriasis drugs market in 2021.
  • North America held leading share of the global market in 2021.
  • The European region is expected to be worth USD 4.23 billion by 2027.
  • The Asia-Pacific region is anticipated to grow at a CAGR of 8.24% during the forecast period.

Psoriasis is a persistent provocative skin problem; it is caused by hereditary air and other natural components. The immune framework plays a significant part being the development of psoriasis. It affixes the existing pattern of skin cells. In psoriasis, cells will, in general, form quickly on the outside of the skin. The extra dermal cells structure scales and red patches, which are bothersome and create itching. Psoriasis drugs include skin creams, oral medicines, and injectables.

MARKET DRIVERS:

The growing incidence of psoriasis, increasing awareness among people regarding the treatment options and growing R&D efforts by the market participants are propelling the global psoriasis drugs market growth.

Psoriasis is a skin condition and is affecting closely 2-3% of the population worldwide. According to the statistics published by National Psoriasis Foundation, nearly 125 million people worldwide and 8 million people in the United States are suffering from psoriasis. An estimated 30% of the people with psoriasis are likely to develop psoriasis arthritis. It is believed that psoriasis impacts the quality of life considerably. In addition, the growing volume of patients taking treatments is propelling global psoriasis drugs market growth. Furthermore, the growing investments to develop innovative products in developing and developing countries and growing awareness among people regarding the various available treatment options to treat psoriasis are anticipated to result in the growth rate of the psoriasis drugs market.

In addition, the growing demand for improved healthcare infrastructure, growing disease burden, rising monitoring from the regulatory bodies regarding the psoriasis drugs and growing efforts from the market participants in terms of R&D are promoting the growth rate of the global psoriasis drugs market. Regulatory bodies such as the U.S. Food and Drug Administration (FDA), The European Medicines Agency (EMA), The Pharmaceuticals and Medical Devices Agency (PMDA) in Japan and The Therapeutic Goods Administration (TGA) in Australia are responsible for evaluating the safety and effectiveness of drugs for the treatment of psoriasis before they are approved for use.

Furthermore, YOY rise in the patient volume suffering from psoriasis is offering growth possibilities to the market participants. The growing investments in healthcare by public and private companies, unmet medical needs, growing healthcare expenditure, growing adoption of technological advancements, and increasing number of changes to the regulatory policies are further promoting the growth rate of the psoriasis drugs market.

MARKET RESTRAINTS:

The high expense of psoriasis treatment is a limitation for the growth of the global psoriasis drugs market. As per a study directed by JAMA Dermatology in 2019, the normal psoriasis medicines with biologics are expensive, pricing between USD 10,000 to USD 25,000 per year. The high cost is due to patent securities are forestalling numerous elective medications. The high cost of psoriasis treatment is a limitation for the psoriasis market. The person or organization (payers) faces challenges deciding which treatment is average to very significant psoriasis to include on their formularies. The report covers the present challenges that relate to each primary psoriasis treatment strategy.

Impact of COVID-19 on the global psoriasis drugs market:

COVID-19 is a pandemic declared by the World Health Organization (WHO). There is an increasing number of people with coronavirus across the world. The global psoriasis drugs market has been slightly affected by the spread of the COVID 19 worldwide. Governments have imposed strict lockdown guidelines in their respective countries to curb the transmission of the disease, which lead to disrupted supply chain and manufacturing units. Though the pharmaceutical companies have increased the production rate due to a ban on flights and restrictions on movement, the growth rate of the psoriasis drugs market has declined in the lockdown period. However, owing to the unlock guidelines by the governments and reduced impact of COVID-19, the psoriasis drugs market is expected to recover quickly and register a healthy CAGR in the coming years.

REPORT COVERAGE:

REPORT METRIC

DETAILS

Market Size Available

2021 to 2027

Base Year

2021

Forecast Period

2022 to 2027

Segments Analysed

By Drug Type, Route of Administration, Target & Region

Various Analyses Covered

Global, Regional & Country Level Analysis, Segment-Level Analysis, DROC, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities

Regions Analysed

North America, Europe, Asia Pacific, Latin America, Middle East, and Africa

 

This research report on the global psoriasis drugs market has been segmented and sub-segmented based on drug type, route of administration, target, and region.

Psoriasis Drugs Market - By Drug Type:

  • Pharmaceuticals
  • Biopharmaceuticals

Based on the drug type, the pharmaceutical is expected to lead the global psoriasis drugs market during the forecast period due to the rising scale of the hospitals and increasing patient pool.

However, the biopharmaceuticals segment had considerable share in the global market in 2021 and is predicted to showcase a healthy CAGR in the coming years.

Psoriasis Drugs Market - By Route of Administration:

  • Topical
  • Systemic
    • Oral
    • Intravenous
    • Others

Based on the route of administration, the topical segment had the largest share of the global psoriasis drugs market in 2021. Topical is the first line of treatment of psoriasis and the awareness regarding the topical treatment procedures is increasing among the public, which are anticipated to result in the segmental growth. For better results, the topical route of administration is used in a single with a combination of other therapies. When the topical treatment fails, or the patient doesn’t respond, Systemic drugs are used.

The systemic segment is gaining attention and is expected to be growing at a higher CAGR during the forecast period.

Psoriasis Drugs Market - By Target:

  • Tumour Necrosis Factor (TNF)
  • Phosphodiesterase Type 4 (PDE4)
  • Interleukin

Based on the target, the tumour necrosis factor (TNF) segment is gaining traction and is anticipated to hold good occupancy in the market during the forecast period owing to the growing incidence of the target disease and rapid adoption of advanced technologies.

Psoriasis Drugs Market - By Region:

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

Geographically, the North American psoriasis drugs market is expected to command a significant share in the global market during the forecast period, followed by Europe. The growth of the regional market is driven by the growing awareness among people regarding the treatment options for psoriasis, increasing incidence of psoriasis across the North American region and rising number of developments in the healthcare systems. The U.S. market is showing significant domination in the North American region as of now, followed by Canada. The growing number of people suffering from psoriasis, well-established healthcare infrastructure, the presence of key market participants and growing number of initiatives from the U.S. government are a few of the factors propelling the U.S. psoriasis drugs market.

The Asia Pacific psoriasis drugs market is anticipated to be the fastest-growing regional segment worldwide during the forecast period. The Asia-Pacific region saw notable improvements in the psoriasis treatment procedures in the recent past. The growing awareness among people regarding the early diagnosis of disease is another major attribute leading to the regional market growth.

The psoriasis drugs market in Europe held substantial share of the global market in 2021. The European region is also anticipated to grow at a healthy CAGR in the coming years. Increasing improvements in the healthcare system across the European region coupled with the growing availability of new and innovative treatments are boosting the psoriasis drugs market in the European region. Companies such as Novartis, Johnson & Johnson, and Pfizer are playing a notable role in the European market and offering a range of treatments, including biologics, small molecules, and topical therapies.

The Latin American psoriasis drugs market is estimated to hold considerable share of the global market during the forecast period.

The psoriasis drugs market in MEA is expected to register a healthy CAGR in the coming years.

KEY MARKET PLAYERS:

Companies that are playing a promising role in the global psoriasis drugs market profiled in the report are Johnson & Johnson (USA), Novartis International AG (Switzerland), Pfizer Inc (USA), Merck and Co. Inc (USA), Celgene Corporation (USA), Janssen Biotech Inc (USA), Stiefel Laboratories Inc (USA), Takeda Pharmaceutical Company Limited (Japan), Amgen (USA), and AbbVie (USA).

RECENT HAPPENINGS IN THIS MARKET:

In November 2019, Amgen (NASDAQ: AMGN) announced its completion of obtaining of overall rights to Otezla® (apremilast), the solitary oral, non-biologic treatment for moderate-to-serious plaque psoriasis and psoriatic joint pain. Otezla was obtained from Celgene Corporation (NASDAQ: CELG) regarding its recently declared consolidation with Bristol-Myers Squibb Company (NYSE: BMY), which was completed.

Please wait. . . . Your request is being processed

FAQ's

How big is the global psoriasis drugs market?

The global psoriasis drugs market size was worth USD 8.75 billion in 2021.

Does this report include the impact of COVID-19 on the psoriasis drugs market?

Yes, we have studied and included the COVID-19 impact on the global psoriasis drugs market in this report.

Which region will lead the psoriasis drugs market in the future?

Geographically, the APAC region is expected to register fastest CAGR in the global market during the forecast period.

Who are the leading players in the psoriasis drugs market?

Johnson & Johnson (USA), Novartis International AG (Switzerland), Pfizer Inc (USA), Merck and Co. Inc (USA), Celgene Corporation (USA), Janssen Biotech Inc (USA), Stiefel Laboratories Inc (USA), Takeda Pharmaceutical Company Limited (Japan), Amgen (USA), and AbbVie (USA) are some of the notable companies in the psoriasis drugs market.

Related Reports

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2500

Didn’t find what you’re looking for?
TALK TO OUR ANALYST TEAM

Need something within your budget?
NO WORRIES! WE GOT YOU COVERED!

REACH OUT TO US

Call us on: +1 888 702 9696 (U.S Toll Free)

Write to us: sales@marketdataforecast.com

Click for Request Sample